

What is claimed is:

1. A method of treating a patient having an amyloid deposition disease comprising the step of administering to the patient

5 a) a therapeutically effective dose of at least one immunoglobulin polypeptide or a fragments thereof, wherein the immunoglobulin polypeptide or fragment thereof binds to an amyloid fibril; and

b) a pharmaceutically acceptable carrier.

10 *bind* 2. The method of claim 1, wherein the immunoglobulin polypeptide or fragment thereof is raised against an immunoglobulin light-chain.

fibril 3. The method of claim 1, wherein binding of the immunoglobulin polypeptide or fragment thereof opsonizes the amyloid fibril.

15 4. The method of claim 1, wherein the immunoglobulin polypeptide or fragment thereof is a monoclonal antibody.

20 5. The method of claim 4, wherein the monoclonal antibody is a humanized antibody.

6. The method of claim 4, wherein the monoclonal antibody is a chimeric antibody.

25 7. The method of claim 6, wherein the chimeric antibody is a humanized antibody.

8. The method of claim 4, wherein the antibody is a labeled antibody.

30 9. The method of claim 4, wherein the monoclonal antibody is selected from the group consisting of $\kappa 1$ (57-18H12), $\kappa 4$ (11-1F4), $\lambda 8$ (31-8C7), and combinations thereof.

shy

10. An immunoglobulin polypeptide or fragment thereof that binds to an amyloid fibril and is effective to enhance the cellular immune response of a patient to remove disease-associated amyloid fibril deposits.

5 11. The immunoglobulin polypeptide or fragment thereof of claim 10, wherein the immunoglobulin polypeptide or fragment thereof is a monoclonal antibody or fragment thereof.

10 12. The immunoglobulin or fragment thereof of claim 11, wherein the monoclonal antibody is a humanized antibody.

15 13. The immunoglobulin polypeptide or fragment thereof of claim 11, wherein the monoclonal antibody is a chimeric antibody.

20 14. The immunoglobulin polypeptide or fragment thereof of claim 13, wherein the chimeric antibody is a humanized antibody.

25 15. The immunoglobulin polypeptide or fragment thereof of claim 11, wherein the antibody is a labeled antibody.

30 16. The immunoglobulin polypeptide or fragment thereof of claim 11, wherein the monoclonal antibody is selected from the group consisting of $\kappa 1$ (57-18H12), $\kappa 4$ (11-1F4), $\lambda 8$ (31-8C7), and combinations thereof.

 17. The monoclonal antibody or fragment thereof of claim 16, wherein the monoclonal antibody is a humanized antibody.

 18. The immunoglobulin polypeptide or fragment thereof of claim 10, wherein the immunoglobulin polypeptide or fragment thereof has been raised against synthetic amyloid fibrils.

19. A pharmaceutical composition comprising the immunoglobulin peptide or fragment thereof of claim 10.

5 20. A nucleic acid molecule which encodes a polypeptide comprising at least a hypervariable region of the immunoglobulin polypeptide of claim 10.

21. A host cell comprising a nucleic acid molecule of claim 20.

10 22. A method of producing an immunoglobulin polypeptide comprising the step of culturing the host cell of claim 21.

agb
#2